Gastric Cancer Drug Market Report 2025 (Global Edition)

Global Gastric Cancer Drug Market Report 2024 Market Size Split by Disease Type (Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Others), by Drug class (PD-1/PD-L1 Inhibitor...

Gastric Cancer Drug Market Report Description

We have various report editions of Gastric Cancer Drug Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Gastric Cancer Drug Market Insights Video

Competitive Landscape of the Gastric Cancer Drug Market

The competitive landscape of the gastric cancer drug market is marked by a dynamic interplay of established pharmaceutical companies and emerging biotech firms. Leading pharmaceutical companies, such as Pfizer, Roche dominate the market with their extensive portfolios of approved gastric cancer therapies, including both conventional chemotherapies and innovative targeted treatments. These companies leverage their strong R&D capabilities and substantial financial resources to drive the development of new therapies and expand their market presence.

March 2023: Akeso, Inc., completed the patient enrollment for its pivotal Phase III clinical trial involving cadonilimab (PD-1/CTLA-4 bi-specific antibody, AK104), which stands as the world's pioneering dual-immune checkpoint bi-specific antibody drug to be approved and brought to market. (Source: https://www.akesobio.com/en/media/akeso-news/230314/) January 2023: Eisai Co., Ltd publicized the presentation of research across various types of gastrointestinal cancers during the 2023 American Society of Clinical Oncology (ASCO) gastrointestinal cancers symposium (#GI23), which took place in person in San Francisco, California. (Source: https://www.eisai.com/news/2023/news202308.html)

Top Companies Market Share in Gastric Cancer Drug Industry: (In no particular order of Rank)

• AbbVie Inc.
• AROG Pharmaceuticals INC.
• AstraZeneca Plc
• Bayer AG
• Biocon Ltd.
• Blueprint Medicines Corp.
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Co.
• Celltrion Co. Ltd.
• Dr Reddys Laboratories Ltd
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Gastric Cancer Drug Market

Which Region Dominates the Gastric Cancer Drug Market in 2024?

According to Cognitive Market Research, North America leads the Gastric Cancer Drug Market due to several factors. The region boasts advanced healthcare infrastructure and high investment in oncology research and development. Additionally, the presence of major pharmaceutical companies and significant healthcare expenditure contribute to market dominance. High incidence rates and a well-established regulatory framework further support the availability of innovative treatments.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific is the fastest-growing region in the Gastric Cancer Drug Market due to its rapidly increasing cancer incidence rates and expanding healthcare infrastructure. The region benefits from rising economic growth, improving access to advanced medical treatments, and increased healthcare investments. Growing awareness and early detection of gastric cancer, combined with the rising prevalence of risk factors, such as dietary habits and smoking, drive demand for effective drugs.

The current report Scope analyzes Gastric Cancer Drug Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Gastric Cancer Drug Market

According to Cognitive Market Research, the global Gastric Cancer Drug market size was estimated at USD 5484.2 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 2193.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Gastric Cancer Drug market with a market size of USD 1730.81 million in 2024 and is projected to grow at a CAGR of 11.0% during the forecast period. The nation's advancements in treatment modalities and a growing patient population.
• The Canada Gastric Cancer Drug market had a market share of USD 263.24 million in 2024 and is projected to grow at a CAGR of 12.0% during the forecast period. Canada's advancements in treatment modalities and a growing patient population.
• The Mexico Gastric Cancer Drug market is projected to witness growth at a CAGR of 11.7% during the forecast period, with a market size of USD 199.62 million in 2024.

Europe Gastric Cancer Drug Market

According to Cognitive Market Research, the global Gastric Cancer Drug market size was estimated at USD 5484.2 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 1645.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.5% from 2024 to 2031.

• The United Kingdom Gastric Cancer Drug market had a market share of USD 276.40 million in 2024 and is projected to grow at a CAGR of 12.3% during the forecast period. In the UK, Gastric Cancer Drug sales witness an upswing due to the nation's rigorous research initiatives and a strong regulatory framework.
• The France Gastric Cancer Drug market is projected to witness growth at a CAGR of 10.7% during the forecast period, with a market size of USD 151.36 million in 2024.
• According to Cognitive Market Research, the German Gastric Cancer Drug market size was valued at USD 325.76 million in 2024 and is projected to grow at a CAGR of 11.7% during the forecast period. In Germany, Gastric Cancer Drug surged due to the rigorous research initiatives and a strong regulatory framework.
• The Italy Gastric Cancer Drug market is projected to witness growth at a CAGR of 10.9% during the forecast period, with a market size of USD 141.49 million in 2024.
• The Russia Gastric Cancer Drug market is projected to witness growth at a CAGR of 10.5% during the forecast period, with a market size of USD 255.02 million in 2024.
• The Spain Gastric Cancer Drug market is projected to witness growth at a CAGR of 10.6% during the forecast period with a market size of USD 134.91 million in 2024
• The Luxembourg Gastric Cancer Drug market is projected to witness growth at a CAGR of 11.6% during the forecast period, with a market size of USD 51.00 million in 2024.
• The Portugal Gastric Cancer Drug market is projected to witness growth at a CAGR of 11.3% during the forecast period, with a market size of USD 34.55 million in 2024.
• The Greece Gastric Cancer Drug market is projected to witness growth at a CAGR of 11.8% during the forecast period, with a market size of USD 19.74 million in 2024.
• Rest of Europe's Gastric Cancer Drug market is projected to witness growth at a CAGR of 10.2% during the forecast period, with a market size of USD 255.02 million in 2024.

Asia Pacific Gastric Cancer Drug Market

According to Cognitive Market Research, the global Gastric Cancer Drug market size was estimated at USD 5484.2 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 1261.37 million in 2024 and will grow at a compound annual growth rate (CAGR) of 15.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Gastric Cancer Drug market size was valued at USD 567.61 million in 2024 and is projected to grow at a CAGR of 14.5% during the forecast period. Gastric Cancer Drug surged in China due to the increasing healthcare access.
• The Japan Gastric Cancer Drug market is projected to witness growth at a CAGR of 13.5% during the forecast period, with a market size of USD 174.07 million in 2024.
• The India Gastric Cancer Drug market had a market share of USD 151.36 million in 2024 and is projected to grow at a CAGR of 16.8% during the forecast period. India's increasing healthcare access.
• The South Korean Gastric Cancer Drug market is projected to witness growth at a CAGR of 14.1% during the forecast period, with a market size of USD 126.14 million in 2024.
• The Australian Gastric Cancer Drug market is projected to witness growth at a CAGR of 14.7% during the forecast period, with a market size of USD 65.59 million in 2024.
• The South East Asia Gastric Cancer Drug market is projected to witness growth at a CAGR of 16.0% during the forecast period, with a market size of USD 87.03 million in 2024.
• The Rest of Asia Pacific Gastric Cancer Drug market is projected to witness growth at a CAGR of 14.8% during the forecast period, with a market size of USD 89.56 million in 2024.

South America Gastric Cancer Drug Market

According to Cognitive Market Research, the global Gastric Cancer Drug market size was estimated at USD 5484.2 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 274.21 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.4% from 2024 to 2031. .

• According to Cognitive Market Research, the Brazil Gastric Cancer Drug market size was valued at USD 117.36 million in 2024 and is projected to grow at a CAGR of 13.0% during the forecast period. Gastric Cancer Drugs flourished in Brazil due to the increasing investment in healthcare infrastructure.
• Argentina's Gastric Cancer Drug market had a market share of USD 46.07 million in 2024 and is projected to grow at a CAGR of 13.3% during the forecast period. Argentina's increasing investment in healthcare infrastructure.
• Colombia Gastric Cancer Drug market is projected to witness growth at a CAGR of 12.2% during the forecast period, with a market size of USD 24.40 million in 2024.
• Peru Gastric Cancer Drug market is projected to witness growth at a CAGR of 12.6% during the forecast period, with a market size of USD 22.49 million in 2024.
• Chile Gastric Cancer Drug market is projected to witness growth at a CAGR of 12.7% during the forecast period, with a market size of USD 19.74 million in 2024.
• The Rest of Latin America's Gastric Cancer Drug market is projected to witness growth at a CAGR of 11.5% during the forecast period, with a market size of USD 44.15 million in 2024.

Middle East and Africa Gastric Cancer Drug Market

According to Cognitive Market Research, the global Gastric Cancer Drug market size was estimated at USD 5484.2 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 109.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.7% from 2024 to 2031..

• The GCC Countries Gastric Cancer Drug market is projected to witness growth at a CAGR of 13.5% during the forecast period, with a market size of USD 46.94 million in 2024. Gastric Cancer Drug sales flourish due to the increasing healthcare investments and a growing focus on cancer treatment.
• The Egypt Gastric Cancer Drug market is projected to witness growth at a CAGR of 13.0% during the forecast period, with a market size of USD 11.52 million in 2024.
• The South Africa Gastric Cancer Drug market is projected to witness growth at a CAGR of 13.7% during the forecast period, with a market size of USD 17.33 million in 2024. Gastric Cancer Drug sales flourish in South Africa due to increasing healthcare investments and a growing focus on cancer treatment.
• The Turkey Gastric Cancer Drug market is projected to witness growth at a CAGR of 12.2% during the forecast period, with a market size of USD 9.43 million in 2024.
• The Nigeria Gastric Cancer Drug market is projected to witness growth at a CAGR of 11.8% during the forecast period, with a market size of USD 11.52 million in 2024.
• The Rest of MEA Gastric Cancer Drug market is projected to witness growth at a CAGR of 11.7% during the forecast period, with a market size of USD 12.94 million in 2024.

Gastric Cancer Drug Market Analysis

How are Segments Performing in the Global Gastric Cancer Drug Market?

Gastric Cancer Drug Market Disease type Segment Analysis

According to Cognitive Market Research, Adenocarcinoma is the dominant disease type in the gastric cancer drug market. This predominance is due to adenocarcinoma being the most common form of gastric cancer, accounting for the majority of cases diagnosed. The high prevalence of adenocarcinoma drives significant demand for targeted treatments and drugs tailored to this specific type of cancer.

Gastrointestinal stromal tumors (GISTs) are the fastest-growing category in the gastric cancer drug market. The rapid growth is attributed to increasing awareness and advancements in targeted therapies specifically designed for GISTs. With the development of drugs like imatinib that target specific genetic mutations associated with GISTs, there has been a significant improvement in diagnosis and treatment outcomes.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Gastric Cancer Drug Industry. Request a Free Sample PDF!

Gastric Cancer Drug Market Drug class Segment Analysis

According to Cognitive Market Research, PD-1/PD-L1 inhibitors are the dominant drug class in the gastric cancer market due to their advanced and effective approach to cancer treatment. These inhibitors, such as pembrolizumab and nivolumab, have revolutionized treatment by harnessing the body's immune system to target and destroy cancer cells. The widespread use and proven efficacy of these drugs in clinical trials and their approval by regulatory bodies have cemented their dominant position in the market.

VEGFR2 antagonists represent the fastest-growing drug class in the gastric cancer drug market. The rapid growth is driven by the increasing recognition of their role in inhibiting tumor angiogenesis, which is crucial for cancer progression. Drugs like ramucirumab, which target the VEGFR2 pathway, have shown significant promise in extending patient survival by preventing the formation of new blood vessels that tumors need to grow.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Gastric Cancer Drug Route of administration Segment Analysis

Gastric Cancer Drug Market Route of administration Segment Analysis

According to Cognitive Market Research, Injectable drugs are the dominant route of administration in the gastric cancer drug market. This dominance is largely due to the effectiveness of injectables in delivering high doses of medication directly into the bloodstream, ensuring rapid and reliable therapeutic effects. Injectable formulations, such as monoclonal antibodies and immune checkpoint inhibitors, are often preferred for their potent and immediate action against cancer cells.

Oral drugs are the fastest-growing route of administration in the gastric cancer drug market. The rapid growth is fueled by the increasing development of new oral formulations that offer the convenience of self-administration and improved patient compliance. Oral medications, such as targeted therapies and small molecules, provide a less invasive alternative to injectables and can be easily integrated into patients' daily routines.

• Oral
• Injectable

Gastric Cancer Drug Distribution Channel Segment Analysis

Gastric Cancer Drug Market Distribution Channel Segment Analysis

According to Cognitive Market Research, Hospital pharmacies are the dominant distribution channel in the gastric cancer drug market. This dominance stems from the critical role hospital settings play in the administration and management of complex cancer therapies. Hospital pharmacies are equipped to handle the specialized needs of gastric cancer patients, including the provision of high-cost medications and the management of drug interactions.

Specialty and retail pharmacies are the fastest-growing distribution channel in the gastric cancer drug market. This rapid growth is driven by the increasing availability of targeted therapies and oral medications that can be conveniently dispensed at retail locations. Specialty pharmacies, in particular, are expanding their role in providing specialized drugs and patient support services, making it easier for patients to access their medications.

• Specialty and Retail Pharmacies
• Hospital Pharmacies
• Others

Author's Detail

Kalyani Raje

Senior Research Analyst at Cognitive Market Research

LinkedIn

Profile

ResearchGate Profile: https://www.researchgate.net/profile/Kalyani-Raje

An optimistic Senior Research Analyst with years of experience in competitive assessment and business consulting. A seasoned professional and subject-matter expert (SME) in the Automobile and transportation vertical.

Author's Conclusion